Clin2
NCT01403402Possibly a fitRecruiting

Study of congenital muscle disease patients and their families

Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) DeficiencyAlpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C))Alpha-Dystroglycanopathy (Fukuyama CMD)Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I))

Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Genetic & congenital, Mental health clinical trials.

This trial collects health information from patients with certain inherited (genetic) muscle diseases and from their families. It may help researchers better understand the disease and improve care by learning what symptoms and treatments patients experience over time.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
4,000 people
Ages
Any age
Study type
Observational

Who can take part

  • You have a genetic (inherited) muscle disease in the study’s listed groups
  • Your condition is one of the approved muscle disease types (not one of the excluded types)
  • You and/or your family can share medical details by report (paper or online forms)
  • You (and/or your caregiver) can answer questions about symptoms and care

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06924125Recruiting
Natural history study for LAMA2 muscular dystrophy

This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.

Barcelona, Barcelona
NCT06078553Recruiting
Natural history study of congenital myasthenic syndromes (CMS)

This study follows people with congenital myasthenic syndrome (CMS) caused by changes in certain genes (DOK7, MUSK, AGRN, or LRP4) over time. It does not test any new drug, but helps researchers understand how the condition changes and how to plan future treatments.

Sacramento, California
NCT07125040Recruiting
Understanding LAMA2 muscle disease over time

This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.

Milan
NCT01353430Recruiting
Study of a rare muscle condition linked to Paget bone disease

This study looks at people and families with a rare muscle weakness condition that can be linked with Paget disease of the bone (and sometimes frontotemporal dementia). It aims to better describe how these conditions appear and relate, which can help future research and care.

Irvine, California
NCT00313677Recruiting
Trial readiness for dystroglycan-related muscle conditions

This trial is for people who have signs that they may have a dystroglycanopathy—a group of muscle conditions. It helps study how ready participants are for care and possibly future treatments by using lab and genetic/pathology information to confirm the condition.

Iowa City, Iowa
NCT05989620Recruiting
Long-term study of muscular dystrophy functions

This study tracks changes in muscle strength and breathing over time in people with certain types of muscular dystrophy. It helps researchers develop better tests to measure how the disease progresses.

Richmond, Virginia

Hear when a new Merosin Deficient CMD (Full or Partial) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.